Position in JANX
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$6,163,218
+$3,632,754 QoQ
Shares Held
443,397
+141.8% QoQ
Ownership
0.727%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in JANX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026ALGERT GLOBAL LLC holds $437,724,004 across 106 Biotechnology names. JANX ranks #26 (1.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ROIV |
Roivant Sciences Ltd.
|
827,454 | $22,920,475 | |
| 2 | AXSM |
Axsome Therapeutics, Inc.
|
135,460 | $22,895,449 | |
| 3 | SNDX |
Syndax Pharmaceuticals Inc
|
928,568 | $21,691,348 | |
| 4 | PCVX |
Vaxcyte, Inc.
|
363,984 | $21,151,110 | |
| 5 | BBIO |
BridgeBio Pharma, Inc.
|
283,921 | $21,083,973 | |
| 6 | XENE |
Xenon Pharmaceuticals Inc.
|
264,200 | $15,363,230 | |
| 7 | MRNA |
Moderna, Inc.
|
237,418 | $12,060,834 | |
| 8 | VRDN |
Viridian Therapeutics, Inc.\DE
|
563,999 | $11,031,820 |
All Filings in JANX
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6,163,218 | 443,397 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $2,530,464 | 183,367 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $2,156,023 | 88,217 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $2,136,334 | 92,482 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $1,097,820 | 40,660 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $3,478,011 | 64,961 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $1,111,762 | 24,472 | Shares | Sole | 2024-11-12 | |
| No filing history on record for this holder in this stock. | ||||||